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Emerging evidence shows that severe COVID-19 can be complicated by a significant 
coagulopathy, that likely manifests in the form of both microthrombosis and venous 
thromboembolism (VTE).  This recognition has led to the urgent need for practical guidance 
regarding prevention, diagnosis, and treatment of VTE.   
Methods: 
A group of approved panelists developed key clinical questions by using the PICO (population, 
intervention, comparator, and outcome) format that addressed urgent clinical questions 
regarding the prevention, diagnosis and treatment of venous thromboembolism in patients 
with COVID-19. MEDLINE (via PubMed or Ovid), Embase and Cochrane Controlled Register of 
Trials were systematically searched for relevant literature and references were screened for 
inclusion. Validated evaluation tools were used to grade the level of evidence to support each 
recommendation. When evidence did not exist, guidance was developed based on consensus 
using the modified Delphi process. 
Results: 
The systematic review and critical analysis of the literature based on13 PICO questions 
resulted in 22 statements.  Very little evidence exists in the COVID-19 population.  The panel 
thus used expert consensus and existing evidence-based guidelines to craft the guidance 
statements. 
Conclusions: 
The evidence on the optimal strategies to prevent, diagnose, and treat venous 
 






Summary of Recommendations 
1. In the absence of a contraindication, in acutely ill hospitalized patients with COVID-
19, we suggest anticoagulant thromboprophylaxis over no anticoagulant 
thromboprophylaxis. 
2. In the absence of a contraindication, in critically ill patients with COVID-19, we 
recommend anticoagulant thromboprophylaxis over no anticoagulant 
thromboprophylaxis. 
3. In acutely ill hospitalized patients with COVID-19, we suggest anticoagulant 
thromboprophylaxis with low-molecular-weight heparin (LMWH) or fondaparinux 
over anticoagulant thromboprophylaxis with unfractionated heparin (UFH); and we 
recommend anticoagulant thromboprophylaxis with LMWH, fondaparinux or UFH 
over anticoagulant thromboprophylaxis with a direct oral anticoagulant (DOAC). 
Remarks:  The panel favors LMWH and fondaparinux over UFH in order to limit staff 
exposure.  The panel cautions against the use of DOACs in these patients secondary to 
the high risk of rapid clinical deterioration in these patients.  In addition, it is likely that 
many of these patients will be receiving concomitant therapy (antiviral agents or other 
investigational treatments) that can significantly affect the pharmacodynamics of and 
thus bleeding risk associated with the DOACs. 
4. In critically ill patients with COVID-19, we suggest anticoagulant thromboprophylaxis 
with LMWH over anticoagulant thromboprophylaxis with UFH; and we recommend 
 
anticoagulant thromboprophylaxis with LMWH or UFH over anticoagulant 
thromboprophylaxis with fondaparinux or a DOAC. 
Remarks:  The panel favors LMWH over UFH in order to limit staff exposure.  The panel 
strongly cautions against the use of DOACs in critically ill patients secondary to their 
hemodynamic instability, the high likelihood of drug-drug interactions, and the high 
incidence of acute kidney injury in these patients. In addition, there is a lack of evidence 
for anticoagulant thromboprophylaxis even in non-COVID critically ill patients. 
5. In critically ill or acutely ill hospitalized patients with COVID-19, we recommend 
against the use of antiplatelet agents for venous thromboembolism (VTE) prevention. 
6. In acutely ill hospitalized patients with COVID-19, we recommend current standard 
dose anticoagulant thromboprophylaxis over intermediate (LMWH BID or increased 
weight-based dosing) or full treatment dosing, per existing guidelines.  
Remarks:  Although there has been some concern for increased risk of VTE in hospitalized 
COVID-19 patients, there is insufficient data to justify increased intensity anticoagulant 
thromboprophylaxis in the absence of randomized controlled trials. 
7. In critically ill patients with COVID-19, we suggest current standard dose 
anticoagulant thromboprophylaxis over intermediate (LMWH BID or increased 
weight-based dosing) or full treatment dosing, per existing guidelines.  
Remarks:  Although there is anecdotal and observational data that suggest an increased 
VTE risk in critically ill patients with COVID-19, it is not clear if the most severely ill 
COVID-19 patients occupy a different level of risk for VTE than other severely ill 
nonsurgical, medical ICU patients. There is also insufficient data regarding bleeding risk 
 
in this population, and given severity of illness, it may be just as likely that critically ill 
COVID-19 patients are at high risk of adverse bleeding complications. Finally, it is not 
clear that this population has a higher risk of VTE when treated with standard doses of 
anticoagulant thromboprophylaxis per existing guidelines. 
8. In patients with COVID-19, we recommend inpatient thromboprophylaxis only over 
inpatient plus extended thromboprophylaxis after hospital discharge. 
Remarks: Extended thromboprophylaxis in patients with COVID-19 at low risk of bleeding 
should be considered, if emerging data on the post-discharge risk of VTE and bleeding 
indicate a net benefit of such prophylaxis. See text for assumptions indicating net 
benefit. 
9. In critically ill patients with COVID-19, we suggest against the addition of mechanical 
prophylaxis to pharmacological thromboprophylaxis.  
Remarks:  Although there is no evidence supporting the combination of mechanical and 
pharmacological thromboprophylaxis for patients with COVID-19 who are critically ill, it 
is not likely that adding mechanical prophylaxis in this population would cause major 
harm. We recommend that providers adhere to existing guidance regarding the use of 
mechanical thromboprophylaxis. 
10.  In critically ill patients with COVID-19 who have a contraindication to 
pharmacological thromboprophylaxis, we suggest the use of mechanical 
thromboprophylaxis. 
11. In critically ill COVID-19 patients, we suggest against routine ultrasound screening for 
the detection of asymptomatic deep vein thrombosis (DVT). 
 
Remarks:  Although we suggest against a routine screening ultrasound for critically ill 
COVID-19 patients, we note that clinicians should have a low threshold for performing 
ultrasound in patients with a reasonable degree of clinical suspicion for VTE. Lower 
extremity ultrasound should also be part of point of care ultrasound (POCUS), 
particularly in situations like unexplained right ventricular dysfunction, 
unexplained/refractory hypoxemia or in patients with suspected PE who are unable to 
undergo a diagnostic study. (i.e. unstable for transport or advanced renal failure). It 
should be noted that even if clot is not visualized on lower extremity ultrasound, 
pulmonary embolism is not fully excluded. 
12. For acutely ill hospitalized COVID-19 patients with proximal DVT or pulmonary 
embolism (PE), we suggest initial parenteral anticoagulation with therapeutic weight 
adjusted LMWH or intravenous UFH. The use of LWMH will limit staff exposure and 
avoid the potential for heparin pseudo-resistance.  In patients without any drug-to-
drug interactions, we suggest initial oral anticoagulation with apixaban or 
rivaroxaban. Dabigatran and edoxaban can be used after initial parenteral 
anticoagulation. Vitamin K antagonist therapy can be used after overlap with initial 
parenteral anticoagulation. 
Remarks:  The panel has downgraded the most recent ACCP recommendation regarding 
the use of oral anticoagulants in patients hospitalized with COVID-19 secondary to the 
high risk of rapid clinical deterioration in these patients.  In addition, it is likely that 
many of these patients will be on concomitant therapy (antiviral agents or other 
investigational treatments) that can significantly affect the pharmacodynamics of and 
 
bleeding risk associated with the DOACs.  Thus LMWH or UFH are favored over oral 
anticoagulants. 
13. For outpatient COVID 19 patients with proximal DVT or PE and no drug-to-drug 
interactions, we recommend apixaban, dabigatran, rivaroxaban or edoxaban. Initial 
parenteral anticoagulation is needed before dabigatran and edoxaban.  For patients 
who are not treated with a DOAC, we suggest vitamin K antagonists over LMWH (for 
patient convenience and comfort).  Parenteral anticoagulation needs to be 
overlapped with vitamin K antagonists. 
14. In critically ill COVID-19 patients with proximal DVT or PE, we suggest parenteral over 
oral anticoagulant therapy. In critically ill COVID-19 patients with proximal DVT or PE 
who are treated with parenteral anticoagulation, we suggest LMWH or fondaparinux 
over UFH. 
Remarks: UFH might be preferred over LMWH or fondaparinux in patients at high 
bleeding risk (including those with severe renal failure), or in those with overt or 
imminent hemodynamic decompensation due to PE, in whom primary reperfusion 
treatment may be necessary.  The decision to use UFH should be balanced with the risks 
associated with extra staff exposure and issues with heparin resistance as above. 
15. For COVID 19 patients with proximal DVT or PE, we recommend anticoagulation 
therapy for a minimum duration of three months. 
16. In most patients with COVID-19 and acute, objectively confirmed PE not associated 
with hypotension (systolic blood pressure < 90 mm Hg or blood pressure drop of >= 
 
40 mm Hg lasting longer than 15 minutes), we recommend against systemic 
thrombolytic therapy. 
Remarks:  Please see statement 18 for the select patients that may require systemic 
thrombolysis. 
17. In patients with COVID-19 and both acute, objectively confirmed PE and hypotension 
(systolic blood pressure < 90 mm Hg) or signs of obstructive shock due to PE, and who 
are not at high risk of bleeding, we suggest systemically administered thrombolytics 
over no such therapy. 
18. In patients with COVID-19 and acute PE with cardiopulmonary deterioration due to 
PE (progressive increase in heart rate, a decrease in systolic BP which remains >90 
mm Hg, an increase in jugular venous pressure, worsening gas exchange, signs of 
shock (eg, cold sweaty skin, reduced urine output, confusion), progressive right heart 
dysfunction on echocardiography, or an increase in cardiac biomarkers) after 
initiation of anticoagulant therapy who have not yet developed hypotension and who 
have a low risk of bleeding, we suggest systemic thrombolytic therapy over no such 
therapy.   
19. We recommend against the use of any advanced therapies (systemic thrombolysis, 
catheter-directed thrombolysis or thrombectomy) for most patients without 
objectively confirmed VTE. 
Remarks:  Thrombolysis may be considered in select patients when cardiac arrest is 
suspected to be caused by PE and imaging is not obtainable.  We would suggest that 
 
providers consider the differential of RV strain (preexisting pulmonary hypertension, 
high PEEP, severe ARDS) before entertaining the use of empiric thrombolysis. 
20. In those patients with COVID-19 receiving thrombolytic therapy, we suggest systemic 
thrombolysis using a peripheral vein over catheter directed thrombolysis. 
21. In patients with COVID-19 and recurrent VTE despite anticoagulation with 
therapeutic weight adjusted LMWH (and documented compliance), we suggest 
increasing the dose of LMWH by 25 to 30%. 
22. In patients with COVID-19 and recurrent VTE despite anticoagulation with apixaban, 
dabigatran, rivaroxaban or edoxaban (and documented compliance), or vitamin K 
antagonist therapy (in the therapeutic range) we suggest switching treatment to 
therapeutic weight-adjusted LMWH. 
 
Background 
In late December 2019, a novel beta coronavirus, the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease of 2019 (COVID-19) was 
identified.  It was officially declared a pandemic by the World Health Organization (WHO) in 
March of 2020.
1
  Emerging evidence shows that severe COVID-19 can be complicated by 
coagulopathy.  In the most severe cases, this manifests as disseminated intravascular 




The presence of DIC in these patients has been found to be a strong predictor of mortality.  In a 
retrospective review of 183 consecutive patients with COVID-19 at a single institution, Tang and 
 
colleagues noted that 71.4% of nonsurvivors and 0.6% of survivors showed evidence of overt 
DIC (as defined by the validated International Society on Thrombosis and Haemostasis DIC 
score).
3
  The literature also demonstrates that many patients with COVID-19 have highly 
abnormal D-dimer levels which were also prognostic.  The incidence of VTE in COVID-19 
patients is not well defined, but early reports suggest it may be higher than in non-COVID 





The mechanism for this is likely multifactorial.  In fact, it could be argued that the lungs of 
patients with COVID-19 exhibit all components of Virchow’s triad—hypercoagulable state, 
endothelial injury, and stasis of blood flow.  High plasma levels of several proinflammatory 
cytokines (IL-2, IL-7, granulocyte colony-stimulating factor, IP10, MCP1, MIP1A and tumor 
necrosis factor-α) have been observed in COVID-19 patients admitted to the intensive care unit 
(ICU).
2
  As in other critical illnesses, this systemic cytokine storm triggers the coagulation system 
and a hypercoagulable sate.  There is also evidence of significant endothelial injury, as 
evidenced by reports of significantly elevated von Willebrand Factor (VWF) and Factor VIII 
(FVIII)  levels.
16
  Finally, severe COVID-19 is manifested as severe acute respiratory distress 
syndrome (ARDS).  Current evidence-based guidelines recommend positive pressure ventilation 
with high levels of positive end-expiratory pressure (PEEP) and fluid restriction,
17
 both of which 
may lead to decreases in pulmonary blood flow, leading to stasis and microthrombosis. 
 
 
The recognition of the coagulopathy with COVID-19, and the early evidence that suggests that 
thrombosis in these patients is higher than that seen in similarly ill hospitalized patients with 
other respiratory infections has led to the urgent need for practical guidance regarding 
prevention, diagnosis, and treatment of VTE.  Current evidence in this specific population is 
lacking, but reports are emerging daily.  The goal of this guidance statement is to review the 
current evidence that is available and, wherever possible, translate this into practical 
recommendations.  Where this was not possible, the authors would like to remind readers that 
several well-done evidence-based guidelines regarding the management of patients with VTE 
and DIC in the non-COVID population exist and should direct patient care until robust trials can 
be completed in the COVID-19 population.
18-23
  Given the rapidity with which new evidence is 
evolving, the authors consider this to be a living document with plans to update the guidance 
statements as appropriate. 
 
Methods 
The primary aim of this CHEST panel was to provide practical guidance on the most urgent 
questions regarding the prevention, diagnosis, and treatment of VTE in patients diagnosed with 
COVID-19.  CHEST appointed a Chair for the panel (LKM) who recruited panelists based upon 
their established expertise within the field of thromboembolism.  The list of panelists was 
approved by CHEST leadership.  All panel members were educated about the process and 
schedule.  Formal conflict of interest review was not performed by the Professional Standards 
Committee given the timeline for the project, but all panelists were reminded that they would 
be required to disclose all relevant conflicts prior to voting and at the time of submission of the 
 
manuscript to the journal.  The majority of panelists had no conflicts of interest to disclose.  
Two panelists (MC, GL) do not receive any personal honoraria and/or consulting fees, but do 
receive funds that go directly to their institutional research fund.  In order to reduce any 
perceived conflict, they abstained from voting on any statements that had overlap with their 
research or consulting relationships.  Given the time-sensitive nature of the topic amid the 
ongoing COVID-19 pandemic, the schedule spanned over a period of 3 weeks and included 6 
conference calls to discuss topic and question development, literature evaluation using GRADE 
(Grading of Recommendations, Assessment, Development, and Evaluation) methodology, 
discussion of suggested guidance statements, modified Delphi surveys, and manuscript 
development.   
 
Question development and Systematic search 
The panel first proposed and shared questions of clinical interest via email.  The questions were 
then worded in the Population, Intervention, Comparator, Outcome (PICO) format and each 
was discussed during the first conference call. Eighteen PICO questions were originally 
developed, but the panel chose to focus on 13 for this version of the guidance statement (Table 
1).  The panel was divided into pairs who each were assigned 2 or 3 PICO questions.  The pairs 
then conducted comprehensive searches using MEDLINE via PubMed or Ovid, Embase and 
Cochrane Controlled Register of Trials.  Search strategy and the details of search results 
depicted in a PRISMA diagram for each PICO question are available in the online supplement.  
Search strategies and inclusion criteria were broad given the anticipated low level of evidence 
at the time they were conducted. 
 
 
Study selection and evidence assessment 
 
Screening and full text selection were performed in duplicate by the pairs.   No meta-analyses 
or randomized controlled trials were available.  Most of the evidence included retrospective 
cohorts and case series.  Thus, none of the available direct and indirect literature provided 
sufficient evidence for the development of evidence tables or recommendations.  The panel 
agreed that patients with COVID-19 appear to be a unique population with evolving evidence 
that their risk of thrombosis is higher than other hospitalized acutely ill medical or ICU patients.  
When this evidence was enough (albeit very low level) to adjust existing guideline statements, 
the panel made modifications to existing statements from CHEST guidelines.
19,20
  When this was 
not possible, the panel simply applied existing guidance and adjusted the wording to this 
population.  All of the statements in this document are thus expert opinion.  When the 
perceived benefits outweighed perceived risks, the panel chose to “recommend” an 
intervention.  When the balance of risk and benefit was less certain, the panel chose only to 
”suggest” an intervention. 
 
Method for achieving consensus 
Search results and suggestions written by the panel pairs for each PICO question were shared 
with all panel members. During a conference call, suggestions were reviewed and subsequently 
re-written based on panel input. This was followed by another conference call with 100% 
participation, soliciting additional comments and input. All panel members participated in the 
 
development of suggestions to be incorporated in the initial round of the modified Delphi 
survey.  The modified Delphi technique is a widely accepted method for the development of 
consensus among experts.
24
 To achieve consensus, a priori decision was made to conduct up to 
three rounds of anonymous voting or until consensus was achieved (defined a priori as 
consensus agreement at ≥80%  with a minimal response rate of 80%) for each draft 
recommendation, whichever came first. The survey incorporated the suggestions developed by 
all panelists and was developed and reviewed by the panel chair and sent to all panel members 
by a CHEST-designated project coordinator. The project coordinator tallied and reported the 
results of the survey to the group, and all votes were anonymous. The results of the survey 
were shared with all panel members and discussed via conference call. There was 100% survey 
participation from the members and consensus was achieved on all statements.  There were, 
however, several comments regarding clarification of wording and consistency. Following 
discussion and revision of statements, a 2nd round of surveys was distributed, including 14 of 
the original 21 statements in which the panel clarified wording and remarks, and one new 
statement.  There was 100% survey participation and consensus was reached on all 22 
statements in the second survey. 
 
Results and Discussion 
 
VTE Prevalence and Incidence in Hospitalized Patients with COVID-19 
We found 11 studies that reported on VTE rates in patients diagnosed with COVID-19 (Table 
2).
4-14,25
  All 11 were observational reports at high risk for selection bias, and 8/11 were 
 
retrospective. These studies included a total of 1,373 patients, the majority (800 (58.0%)) of 
whom were treated in an ICU. One other study reported 40% (407/1099) of inpatients have a 
high risk for VTE by Padua risk score, but did not report VTE rates.
26
 This study, however, had 
major limitations (e.g., 8% of patients had missing values for age and missing values for other 
variables were not reported).  Prevalence and incidence rates of TE are reported in Tables 3 and 
4.  Given the heterogeneity of the studies, we chose not to pursue a pooled analysis. 
A qualitative review of the 11 studies reporting VTE prevalence and incidence is presented in 
Table 2. Patient selection procedures varied across studies and were often unclear. A detailed 
description of testing procedures was also lacking in most studies. Some studies reported only 
deep vein thrombosis (DVT).
4,12,14
 Only five studies specified whether pulmonary embolism (PE) 
was subsegmental or more proximal,
5,6,9,10,13
 and only three studies provided detailed 
information on DVT location.
6,9,10
 Universal screening for events also varied across studies, and 
in many, outcomes were reported on patients still hospitalized. Average duration of 
hospitalization and or the hospital day on which CTPA or lower extremity compression 
ultrasound (CUS) was performed was variably reported. Lastly, thromboprophylaxis rates in 
Chinese hospitals are reported to be as low as 20% in some studies,
26,27
 which affects 
interpretation of event rates in Chinese COVID-19 populations. 
 
VTE Prevention 
The panel first aimed to address the need for VTE prophylaxis in acutely ill hospitalized (general 
inpatient ward) and critically ill (ICU) patients with COVID-19.  Our search identified 3 single-
center studies reporting estimates for the incidence of VTE in acutely ill hospitalized patients 
 
(Table 2 and 4).
9,10,14
  None of the studies allows for comparison between anticoagulant 
thromboprophylaxis and placebo, or comparison between different drugs or doses. The 
majority of patients included in those studies received anticoagulant thromboprophylaxis at 
prophylactic or higher dose. Lodigiani  and colleagues reported a cumulative incidence of 
venous and arterial thromboembolic events of 6.6% during hospital admission. A total of 2.4% 
of the patients developed a PE, and 0.9% of the patients were diagnosed with a symptomatic 
isolated proximal DVT of the lower extremities.
9
  As reported by Middeldorp et al, the 
cumulative incidence of symptomatic VTE was 9.2% at 14 days, comprising 1 patient with 
proximal PE, 1 patient with subsegmental PE, and 2 patients with distal DVT.
10
 Xu and 




Noteworthy, most COVID-19 patients would have been eligible for at least 1 of the 3 landmark 
randomized controlled trials of anticoagulant thromboprophylaxis in acutely ill medical 
inpatients.
28-30
 In these studies, the proportion of patients who developed symptomatic VTE or 
any VTE at 14-21 days was 0.3-1.0% and 2.8-5.6%, respectively.
28-30
 Because the incidence of 
VTE in acutely ill medical inpatients is too low (below 1% without thromboprophylaxis) to justify 
anticoagulant thromboprophylaxis - and incurred risk of bleeding - in every patient,
19
 several 
risk stratification scores have been developed to identify medical inpatients at higher risk of 
VTE. The Padua and IMPROVE risk scores are the most extensively validated scores,
31,32
 but 
both showed heterogenous discriminatory performance in external validation studies
32-41
 and 
they lack validation in an impact study. Considering that hospitalized patients with COVID-19 




affects many inpatients with COVID-19. Infectious disease is an additional risk factor for VTE,
42
 
which is present in all patients with COVID-19. Taking into account those risk factors and that 
the current estimates of the incidence of VTE in non-critically ill patients with COVID-19 is well 
above 1% even on anticoagulant thromboprophylaxis, the panel considers all hospitalized 
patients with COVID-19 at increased risk of VTE. We therefore suggest against individualized 
VTE risk assessment and suggest anticoagulant thromboprophylaxis in all hospitalized patient 
with COVID-19 in absence of contraindications. 
 
1.  In the absence of contraindications, in acutely ill hospitalized patients with COVID-
19, we suggest anticoagulant thromboprophylaxis over no anticoagulant 
thromboprophylaxis. 
 
Our search identified 11 studies providing estimates for the incidence or prevalence of VTE in 
critically ill patients with COVID-19 (Table 2 and 3).
4-14,25
 None of the studies allows for 
comparison between anticoagulant thromboprophylaxis and placebo, or comparison between 
different drugs. The proportion of critically ill patients with COVID-19 diagnosed with VTE on at 
least standard dose anticoagulant thromboprophylaxis ranged from 0 to 54%;
5-14,25
 the 
reported cumulative incidence of VTE during hospital stay ranged from 20 to 59%.
7,10,11,13
  One 
single-center retrospective cohort study of 449 patients hospitalized in the Tongji hospital in 
Wuhan suggests that heparin at prophylactic dose is associated with an absolute mortality 
reduction of 24% in patients with sepsis-induced coagulopathy (SIC) compared to no 
anticoagulant thromboprophylaxis.
27
 No mortality difference was shown in patients that were 
 
less sick. Considering that low-molecular-weight heparin (LMWH) at prophylactic doses did not 
reduce mortality in a randomized placebo-controlled trial in critically ill patients with chronic 
obstructive pulmonary disease,
43
 the mortality difference in sick patients with COVID-19 
appears striking. However, the study has several major limitations. A total of only 22% of the 
patients received thromboprophylaxis; thromboprophylaxis was defined as the use of heparin 
≥7 days which may have introduced immortal time bias; and the analysis was not adjusted for 
other potential confounders. 
 
In critically ill medical patients without COVID-19, the failure rate of anticoagulant 
thromboprophylaxis in randomized controlled trials ranged from 6 to 16%.
43-45
  The incidence of 
VTE in cohort studies of critically ill medical patients varies depending on patient population.
19
 
Pooled risk estimates for benefits and harms of anticoagulant thromboprophylaxis in critically ill 
medical patients without COVID-19 differ across meta-analyses,
19,22,46
 but practice guidelines 
consistently recommend anticoagulant thromboprophylaxis with LMWH (or unfractionated 
heparin [UFH]) over no such therapy.
19,22
  We recommend anticoagulant thromboprophylaxis in 
all critically ill patients with COVID-19, because current evidence suggest that the failure rate of 
thromboprophylaxis in critically ill patients with COVID-19 seems higher than in randomized 
controlled trials assessing anticoagulant thromboprophylaxis in critically ill medical patients 
without COVID-19 and at least as high as the failure rate in prospective cohort studies of 





2. In the absence of contraindications, in critically ill patients with COVID-19, we 




Choice of Agent 
We did not identify any studies allowing for comparisons between different anticoagulants for 
thromboprophylaxis in acutely ill hospitalized patients with COVID-19. LMWH, UFH, 
fondaparinux, and DOACs have each been assessed in randomized trials of thromboprophylaxis 
in acutely ill hospitalized patients without COVID-19.
22
  Compared to placebo, parenteral 
anticoagulant thromboprophylaxis with LMWH or fondaparinux reduces the risk of 
symptomatic PE and any DVT.
22
 Pooled results indicate no statistically significant difference in 
symptomatic DVT, major bleeding or mortality.
22
  No difference in critical outcomes have been 
shown in randomized trials comparing LMWH and UFH; no randomized study compared 
fondaparinux with LMWH/UFH.
22
   Compared to LMWH, DOACs do not reduce the risk of PE or 
symptomatic DVT, but are associated with an increased risk of major bleeding (relative risk [RR], 
1.70; 95% confidence interval [CI], 1.02-2.82).
48
 Therefore, the panel recommends using LMWH, 
fondaparinux or UFH over the use of DOACs in acutely ill hospitalized patients with COVID-19. 
Considering the reduced nursing staff exposure with LMWH or fondaparinux due to the once-
daily administration and the possibly lower risk of heparin-induced thrombocytopenia with 
LMWH or fondaparinux compared to UFH, we suggest LMWH or fondaparinux over UFH in 
acutely ill hospitalized patients with COVID-19. 
 
 
3. In acutely ill hospitalized patients with COVID-19, we suggest anticoagulant 
thromboprophylaxis with LMWH or fondaparinux over anticoagulant 
thromboprophylaxis with UFH; and we recommend anticoagulant 
thromboprophylaxis with LMWH, fondaparinux or UFH over anticoagulant 
thromboprophylaxis with a DOAC. 
Remarks:  The panel favors LMWH and fondaparinux over UFH in order to limit staff 
exposure.  The panel cautions against the use of DOACs in these patients secondary to 
the high risk of rapid clinical deterioration in these patients.  In addition, it is likely that 
many of these patients will be receiving concomitant therapy (antiviral agents or other 
investigational treatments) that can significantly affect the pharmacodynamics of and 
thus bleeding risk associated with the DOACs. 
 
We did not identify any studies allowing for comparisons between different anticoagulants for 
thromboprophylaxis in critically ill patients with COVID-19. LMWH and UFH are the only 
anticoagulants which have been assessed in randomized trials of thromboprophylaxis in 
critically ill patients without COVID-19. The panel therefore recommends using LMWH or UFH 
over other options such as fondaparinux or DOAC. Pooled results of 3 randomized controlled 
trials indicate no difference between LMWH and UFH in symptomatic DVT, major bleeding, or 
mortality.
19,22
 The Prophylaxis for Thromboembolism in Critical Care Trial (PROTECT) of 3,746 
critically ill patients, showed a lower risk of symptomatic PE with dalteparin 5,000 units daily as 
compared to UFH 5,000 units twice daily (hazard ratio 0.51; 95% CI, 0.30-0.88).
44
 Even though, 
 
this difference was only driven by 19 events, the panel suggests LMWH over UFH for critically ill 
patients with COVID-19, because LMWH has the additional advantages over UFH that it has a 
potential lower risk of heparin-induced thrombocytopenia and that it requires fewer nursing 
staff contact given its once-daily administration regimen. 
 
4. In critically ill patients with COVID-19, we suggest anticoagulant thromboprophylaxis 
with LMWH over anticoagulant thromboprophylaxis with UFH; and we recommend 
anticoagulant thromboprophylaxis with LMWH or UFH over anticoagulant 
thromboprophylaxis with fondaparinux or a DOAC. 
Remarks:  The panel favors LMWH over UFH in order to limit staff exposure.  The panel 
strongly cautions against the use of DOACs in critically ill patients secondary to their 
hemodynamic instability, the high likelihood of drug-drug interactions, and the high 
incidence of acute kidney injury in these patients.  In addition, there is a lack of evidence 
for anticoagulant thromboprophylaxis even in non-COVID critically ill patients. 
 
Our literature search did not identify any randomized trials assessing the efficacy and safety of 
aspirin (or any other antiplatelet agent) for VTE prophylaxis in COVID-19 patients requiring 
hospitalization.  Due to the absence of direct evidence, the guideline panel decided to consider 
indirect evidence available from systematic reviews of randomized controlled trials conducted 
in non-COVID-19 patients. The Antiplatelet Trialists’ Collaboration produced a detailed 
overview of randomized trials in order to determine the efficacy of antiplatelet therapy for VTE 




 In contrast, systematic reviews have shown that heparins reduce the risk for 
developing PE (RR, 0.59; 95% CI, 0.45-0.78), symptomatic proximal DVT (RR, 0.28; 95% CI, 0.06-
1.37), and symptomatic distal DVT (RR, 0.75; 95% CI, 0.17-3.34)
22
.  Based on indirect 
comparisons, we expect the net benefit of anticoagulant thromboprophylaxis in COVID-19 
patients requiring hospitalization to be substantially greater than the benefits of aspirin 
thromboprophylaxis. Consequently, we do not consider antiplatelet agents a reasonable 
alternative to anticoagulant prophylaxis in these patients for VTE events. 
 
5. In critically ill or acutely ill hospitalized patients with COVID-19, we recommend 
against the use of antiplatelet agents for VTE prevention. 
 
Dosing Regimen for Anticoagulant thromboprophylaxis 
 
We found no studies that reported a comparison of one specific anticoagulant 
thromboprophylaxis regimen to another. One retrospective study reported a reduction in 
mortality with heparin at prophylactic doses (most were on 40-60 mg enoxaparin per day) 
compared to no prophylaxis in a highly select group of ICU patients.
27
 This study suffers from 
confounding by indication for prophylaxis and lack of adjustment for co-factors in the specific 
analysis that found a mortality difference with heparin. For all comers in this study, there was 
no mortality difference related to heparin prophylaxis.  In a single-center retrospective study of 
2773 patients of whom 786 (28%) received therapeutic anticoagulation, in-hospital mortality 




Among mechanically ventilated patients, in-hospital mortality was lower in patients who 
received anticoagulation (29%, median survival of 21 days) than in those who did not receive 
anticoagulation (63%, median survival of 9 days). In a multivariable Cox proportional hazards 
model, longer duration of therapeutic anticoagulation was associated with a reduced risk of 
mortality. The risk of major bleeding was 3% and 1.9% in anticoagulated and non-
anticoagulated patients, respectively. Of note, pulmonary hemorrhage was not part of the 
definition of major bleeding and the incidence of VTE was not reported. While this study is 
hypothesis-generating and supports the rationale for randomized controlled trials evaluating 
thromboprophylaxis at therapeutic doses, it should not inform patient management due to its 
limitations. First, the authors did not specify anticoagulant agents, the indication for 
anticoagulation and whether non-anticoagulated patients did receive anticoagulant 
thromboprophylaxis. Second, the results may be flawed by immortal time bias, confounding by 
indication and other residual confounding. Finally, the median duration of anticoagulation was 
3 days which challenges the biological plausibility of the large mortality reduction observed 
among mechanically ventilated patients. 
 Several studies provide data that are indirectly relevant.  A retrospective, observational 
report on 16 ICU patients (all mechanically ventilated and diagnosed with ARDS) reported no 
VTE events in patients who had VTE anticoagulant thromboprophylaxis titrated to serum 
coagulation studies and adjusted for body mass index (BMI).
25
 They used LMWH, anti-thrombin 
concentrate, and clopidogrel, and there is no report on bleeding rates. Several other studies 




 Because all identified studies of VTE rates and anticoagulant thromboprophylaxis 
regimens for hospitalized COVID-19 patients are observational with select populations, 
definitive interpretation is difficult. It seems critically ill, intubated patients with COVID-19 can 
develop a profound coagulopathy and form clot at a high rate despite prophylaxis. While 
adjusting prophylaxis by coagulation studies seems reasonable, specific protocols have not 
been systematically studied nor bleeding rates reported. Of note, several studies have reported 
critically ill COVID-19 patients are at high risk for bleeding based on the IMPROVE bleeding risk 
score.
14,26
  Until we have more data, an accurate risk-benefit assessment of VTE versus 
bleeding, particularly with increasing anticoagulant thromboprophylaxis above standard dosing, 
is not possible. 
 A recent guideline reviewed the data on SIC and DIC in non COVID-19 patients.
23
 The 
authors noted that SIC/DIC can lead to a pro-thrombotic coagulopathy. They concluded 
adjustment to standard anticoagulant thromboprophylaxis in the presence of SIC/DIC remains 
controversial but could be considered. Whether COVID-19 induces a different or more 
profound type of SIC/DIC remains unknown, but even if one assumes it is similar to non-COVID-
19 SIC/DIC, the optimal approach to anticoagulant thromboprophylaxis is uncertain. 
 
6. In acutely ill hospitalized patients with COVID-19, we recommend current standard 
dose anticoagulant thromboprophylaxis over intermediate (LMWH BID or increased 
weight-based dosing) or full treatment dosing, per existing guidelines.  
 
Remarks:  Although there has been some concern for increased risk of VTE in hospitalized 
COVID-19 patients, there is insufficient data to justify increased intensity anticoagulant 
thromboprophylaxis in the absence of randomized controlled trials. 
 
7. In critically ill patients with COVID-19, we suggest current standard dose 
anticoagulant thromboprophylaxis over intermediate (LMWH BID or increased 
weight-based dosing) or full treatment dosing, per existing guidelines.  
Remarks:  Although there is anecdotal and observational data that suggest an increased 
VTE risk in critically ill patients with COVID-19, it is not clear if the most severely ill 
COVID-19 patients occupy a different level of risk for VTE than other severely ill 
nonsurgical, medical ICU patients. There is also insufficient data regarding bleeding risk 
in this population, and given severity of illness, it may be just as likely that critically ill 
COVID-19 patients are at high risk of adverse bleeding complications. Finally, it is not 
clear that this population has a higher risk of VTE when treated with standard doses of 
anticoagulant thromboprophylaxis per existing guidelines. 
 
Duration of Thromboprophylaxis 
 
Our search identified no study reporting incidence of VTE or major bleeding after hospital 
discharge in patients with COVID-19. In non-COVID patients, a significant proportion of VTE 
events associated with hospitalization occur after discharge.
28-30,51
  Anticoagulant 
thromboprophylaxis up to 45 days after discharge reduces the risk of VTE following hospital 
 
admission (RR, 0.61; 95% CI, 0.44-0.83) but increases the risk of major bleeding (RR, 2.04; 95% 
CI, 1.42-2.91).
52
  A post-hoc analysis of the MAGELLAN trial suggests that extended 
thromboprophylaxis is associated with a net benefit in patients at high risk of VTE as per 
modified IMPROVE score and low risk of bleeding (i.e., absence of active cancer, dual 
antiplatelet therapy, history of bronchiectasis or pulmonary cavitation, active gastroduodenal 
ulcer, or any bleeding in the previous 3 months).
53
  However, in the MARINER trial of 12,069 
patients at risk of VTE as per modified IMPROVE score, rivaroxaban 10 mg daily for 45 days 
after hospital discharge did not reduce symptomatic VTE.
54
  The recent American Society of 
Hematology practice guideline recommend against the use of extended thromboprophylaxis, 
because they determined a net harm associated with extended thromboprophylaxis.
22
 Many 
hospitalized patients with COVID-19 would likely have been eligible for randomized controlled 
trials assessing extended thromboprophylaxis and it appears therefore justified to extrapolate 
relative treatment effects from those studies to hospitalized patients with COVID-19. Assuming 
that patients with COVID-19 incur the same risk of bleeding as patients without COVID-19 at 
high risk of VTE (i.e., 0.7% at 35 days after discharge without extended thromboprophylaxis in 
patients at low risk of bleeding)
53
 and that symptomatic VTE is associated with a similar burden 
to patients as major bleeding,
22
 the panel suggests that extended thromboprophylaxis would 
result in a net benefit in patients with COVID-19 at low bleeding risk, if the risk of symptomatic 
VTE would be above 1.8% at 35-42 days after hospital discharge. Despite evidence suggesting a 
higher risk of VTE during hospitalization in patients with COVID-19 than in patients without 
COVID-19, the panel recommends only inpatient anticoagulant thromboprophylaxis, because 
post-discharge VTE and major bleeding rates in COVID-19 patients are currently unknown. 
 
 
8. In patients with COVID-19, we recommend inpatient thromboprophylaxis only over 
inpatient plus extended thromboprophylaxis after hospital discharge. 
Remarks: Extended thromboprophylaxis in patients with COVID-19 at low risk of bleeding 
should be considered, if emerging data on the post-discharge risk of VTE and bleeding 
indicate a net benefit of such prophylaxis. See text for assumptions indicating net 
benefit. 
 
Role of Mechanical Prophylaxis 
 
We were unable to identify any studies that reported on mechanical methods for prophylaxis in 
COVID-19 patients. While it may seem reasonable to add mechanical to pharmacological 
prophylaxis in patients thought to be at high baseline risk for VTE, a recent randomized 
controlled trial found no benefit to this approach.
55
 Therefore, it seems unlikely that 
mechanical, in addition to pharmacological prophylaxis will affect VTE rates in critically ill 
patients with COVID-19. 
 
9. In critically ill patients with COVID-19, we suggest against the addition of mechanical 
thromboprophylaxis to pharmacological thromboprophylaxis.  
Remarks:  Although there is no evidence supporting the combination of mechanical and 
chemical thromboprophylaxis for patients with COVID-19 who are critically ill, it is not 
likely that adding mechanical prophylaxis in this population would cause major harm. 
 
We recommend that providers adhere to existing guidance regarding the use of 
mechanical thromboprophylaxis. 
 
10.  In critically ill patients with COVID-19 who have a contraindication to 
pharmacological thromboprophylaxis, we suggest the use of mechanical 
thromboprophylaxis. 
 
Diagnosis of VTE 
 
Role of Screening Ultrasound 
 
Screening ultrasound for asymptomatic DVT is not routinely performed in critically ill patients. 
Lower extremity ultrasound is reserved for critically ill patients with a clinical suspicion for VTE.  
General screening ultrasound carries an increased risk of personnel exposure and resource 
utilization during the COVID-19 pandemic.  As we have noted, there is growing evidence to 
suggest that patients with COVID-19 are at an increased risk of VTE events.
6,56
  This risk is 
exacerbated in critically ill ICU patients compared those on a general medical ward.
9,10
  
Middeldorp et al, reported an increased incidence of venous thrombosis in ICU (32%) vs non-
ICU patients (1.6%).
10
  Lodigiani et al, reported similar venous thrombosis rates in ICU (4.16%) 
vs non-ICU patients (1.27%).
9
  Cui et al, suggested a 25% (20 out of 81 ICU patients) rate of DVTs 
in their critically ill cohort, but none of the patients in the study were on pharmacological 
thromboprophylaxis.
4
  We found inconsistent methods of ultrasound screening in COVID-19 
 
patients. In the study by Middeldorp et al, ultrasound was performed every 5 days in ICU 
patients, and 10 days prior to data analysis in cross-sectional fashion for general ward 
patients.
10
  In a second study by Lljitos et al, screening ultrasound was performed at the time of 
ICU admission (between day 1 and 3) and then at day 7.
8
  We, therefore suggest against routine 
screening, but suggest a low threshold for performing lower extremity ultrasound or full body 
ultrasound in COVID-19 patients who experience abrupt hypoxemia or clinical deterioration. 
Tables 3 and 4 summarize the reported DVT incidence in the published literature. 
 
11. In critically ill COVID-19 patients, we suggest against routine ultrasound screening for 
the detection of asymptomatic DVT. 
Remarks:  Although we suggest against a routine screening ultrasound for critically ill 
COVID-19 patients, we note that clinicians should have a low threshold for performing 
ultrasound in patients with a reasonable degree of clinical suspicion for VTE. Lower 
extremity ultrasound should also be part of point of care ultrasound (POCUS), 
particularly in situations like unexplained right ventricular dysfunction, 
unexplained/refractory hypoxemia or in patients with suspected PE who are unable to 
undergo a diagnostic study (i.e. unstable for transport or advanced renal failure).  It 
should be noted that even if clot is not visualized on lower extremity ultrasound, PE is not 
fully excluded. 
 
Role of D-dimer and other biomarkers in the diagnosis of VTE 
 
 
Currently, there are few studies that have evaluated either D-dimer levels, at a single cut point 
value or using dynamic change, or other laboratory values, to predict a diagnosis of VTE in 
patients with COVID-19. The lack of systematic surveillance for DVT and PE has severely limited 
the ability to establish a meaningful context for biomarkers.  
 
Two studies described biomarkers, including D-dimer, in relationship to VTE diagnosis but did 
not  describe  systematic evaluation for suspected VTE which must be employed to understand 
sensitivity and specificity
4,6
  Cui et al. reported only DVT rather than DVT and PE- which further 
brings to question which diagnostic procedure was employed as venous ultrasound cannot be 
employed in isolation to diagnose PE.  Furthermore, it was not clear what diagnostic imaging 
was employed and if imaging was triggered by clinical parameters or as screening as only DVTs 
were found. The study suggested a 94% negative predictive value for D-dimer cut off of 1.0 
ug/ml but did not compare to other biomarkers which correlated with VTE.
4
  They also reported 
that other laboratory markers correlated with increased risk of VTE including the aPTT and 
lymphocyte count, but did not evaluate single cut points or trending values. Klok et al.
6
 did not 
report on D-dimer levels but noted that prolongation of the PT >3 seconds or the aPTT >5 





 did not report on VTE incidence but noted derangement in coagulation and clotting 
markers -PT, aPTT, D-dimer, fibrin degradation products- were higher in non-survivors. 
Dramatic increase of D-dimer also correlated with increase in all-cause mortality.  It may follow 
 
that thrombosis is a major contributor to increase in all-cause mortality, as survival improved 
when patients received parenteral anticoagulation.
27
  In conclusion, there is insufficient data to 
guide clinical practice for VTE diagnosis based on laboratory values.  We suggest as in other 
inpatient populations biomarkers not be employed in the diagnostic evaluation for suspected 




Our literature search did not identify any randomized trials assessing the efficacy and safety of 
anticoagulants for the treatment of acute VTE in hospitalized or critically ill COVID-19 patients. 
 
Although clinical practice guidelines recommend the use of DOACs for the vast majority of 
patients with acute symptomatic VTE
20,21
, there are reasons to make different suggestions for 
the preferred anticoagulant in patients with COVID-19, particularly for the critically ill: 1) many 
of these patients require administration of inhibitors or inducers of P-glycoprotein (P-gp) or 
strong inhibitors or inducers of cytochrome P450 (CYP) enzymes. Treatment with potent P-gp 
inhibitors (e.g., antiretrovirals, azithromycin, others) was an exclusion criterion in most 
landmark randomized trials that assessed the efficacy and safety of DOACs in patients with 
acute VTE. 
57-60
  A recent study enrolled 12 consecutive patients on DOACs who were 
hospitalized with severe COVID-19.
61
  For each patient, C-trough DOAC level was compared 
with the one measured before hospitalization. On average, C-trough levels were 6 times higher 
during hospitalization than in the pre-hospitalization period; 2) gastrointestinal dysfunction is a 
 
common problem in the critically ill patient, and can significantly affect the pharmacokinetics of 
oral drugs; and 3) acute renal failure is also common in the setting of critical illness, and DOACs 
are contraindicated in patients with severe (e.g., creatinine clearance <30 mL/min) renal failure. 
For these reasons, the panel endorsed that in critically ill COVID-19 patients with proximal DVT 
or PE, parenteral anticoagulation might be preferred to oral anticoagulant therapy. 
 
Unfractionated heparin has an unpredictable dose response and a narrow therapeutic window; 
therefore, monitoring is essential to ensure optimal efficacy and safety. Alternatively, LMWHs 
and fondaparinux have more predictable pharmacokinetics and a greater bioavailability than 
UFH. Due to these pharmacologic features, body weight-adjusted doses of LMWH or 
fondaparinux can be administered subcutaneously without laboratory monitoring in the 
majority of these patients. UFH, not LMWH, can be effected by the phenomenon of heparin 
resistance which can “pseudo”, in which the aPTT does not reflect the anti Xa effect (best 
managed by avoiding the aPTT and monitoring by anti Xa levels), and true resistance in which 
case acute phase reactants common in inflammatory states increase UFH clearance and can 
greatly increase the doses required. The former situation is common with elevated FVIII levels, 
common in COVID-19 patients.  The latter situation may delay attainment of therapeutic levels 
of anticoagulation, which is highly undesirable in an acute VTE situation.
62,63
  Based on this, and 
to avoid risk of exposure for staff, we suggest that LMWH or fondaparinux be used over UFH in 
critically ill COVID-19 patients with proximal DVT or PE. UFH might be preferred over LMWH or 
fondaparinux in patients at high bleeding risk (including those with severe renal failure 
[creatinine clearance <30 mL/min]), or in those with overt or imminent hemodynamic 
 
decompensation due to PE, in whom primary reperfusion treatment may be necessary).  
Outpatients with COVID-19 and acute PE have not been described, but the approach to these 
patients can follow existing guidelines.  Patients with VTE in the setting of COVID-19 are 
considered to have a provoking factor, and thus initial treatment should be for at least three 
months. 
 
12. For acutely ill hospitalized COVID-19 patients with proximal DVT or PE, we suggest 
initial parenteral anticoagulation with therapeutic weight adjusted LMWH or 
intravenous UFH. The use of LWMH will limit staff exposure and avoid the potential 
for heparin pseudo-resistance.  In patients without any drug-to-drug interactions, we 
suggest initial oral anticoagulation with apixaban or rivaroxaban. Dabigatran and 
edoxaban can be used after initial parenteral anticoagulation. Vitamin K antagonist 
therapy can be used after overlap with initial parenteral anticoagulation. 
Remarks:  The panel has downgraded the most recent ACCP recommendation regarding 
the use of oral anticoagulants in patients hospitalized with COVID-19 secondary to the 
high risk of rapid clinical deterioration in these patients.  In addition, it is likely that 
many of these patients will be on concomitant therapy (antiviral agents or other 
investigational treatments) that can significantly affect the pharmacodynamics of and 




13.  For outpatient COVID 19 patients with proximal DVT or PE and no drug-to-drug 
interactions, we recommend apixaban, dabigatran, rivaroxaban or edoxaban. Initial 
parenteral anticoagulation is needed before dabigatran and edoxaban.  For patients 
who are not treated with a direct oral anticoagulant, we suggest vitamin K 
antagonists over LWMH (for patient convenience and comfort).  Parenteral 
anticoagulation needs to be overlapped with vitamin K antagonists. 
 
14. In critically ill COVID-19 patients with proximal DVT or PE, we suggest parenteral over 
oral anticoagulant therapy. In critically ill COVID-19 patients with proximal DVT or PE 
who are treated with parenteral anticoagulation, we suggest LMWH or fondaparinux 
over UFH. 
Remarks: UFH might be preferred over LMWH or fondaparinux in patients at high 
bleeding risk (including those with severe renal failure), or in those with overt or 
imminent hemodynamic decompensation due to PE, in whom primary reperfusion 
treatment may be necessary.  The decision to use UFH should be balanced with the risks 
associated with extra staff exposure and issues with heparin resistance as above. 
 
15. For COVID 19 patients with proximal DVT or PE, we recommend anticoagulation 





Our literature search did not identify any randomized trials or prospective cohort studies 
assessing the efficacy or safety of any thrombolytic therapies for the management of critically ill 
patients with COVID-19 without objective evidence of VTE and VTE-associated hypotension.  
This includes either systemic delivery or catheter-directed thrombolysis. 
  
Due to the absence of direct evidence, the guideline panel decided to consider indirect 
evidence from another population of patients receiving thrombolysis.  In a randomized trial of 
normotensive patients without COVID-19 but with objectively confirmed PE and right heart 
strain, systemic thrombolysis was associated with major bleeding in 11.5% of patients.
64
  The 
risk of major bleeding has not been systematically assessed during COVID-19.  Diffuse alveolar 
damage
15
 and frank alveolar hemorrhage have been identified in autopsy specimens from 
COVID-19 patients
65
, suggesting bleeding risk could be high.  Therefore, we recommend against 
thrombolytic therapy in COVID-19 patients without objectively confirmed PE and PE-induced 
hypotension (systolic blood pressure <90 mm Hg or blood pressure drop >= 40 mm Hg lasting 
for longer than 15 minutes).
20,21
  
Patients with objectively confirmed PE who are normotensive represent a wide spectrum of 
disease.  Some are very low risk of adverse outcome.  Others are at the more severe end of the 
spectrum, and may present with signs, imaging, or laboratory markers that suggest the 
presence of right ventricular dysfunction.  As we have stated in earlier CHEST Guidelines,
20
 
these patients should be monitored closely for signs of deterioration.  Clearly patients who 
develop hypotension meet criteria for thrombolytic therapy.  Deterioration that has not 
resulted in frank hypotension may also prompt the use of thrombolytic therapy (progressive 
 
increase in heart rate, progressive decrease in systolic blood pressure, an increase in jugular 
venous pressure, worsening gas exchange, signs of shock, progressive right heart dysfunction 
on echocardiography, or an increase in cardiac biomarkers).  This recommendation was based 
on the trial by Meyer et al, in which almost 90% of patients with intermediate risk PE who 
received rescue thrombolysis survived.
64
 
 None of the existing scores for assessing bleeding risk in patients with VTE have been studied 
or validated in patients with COVID-19.  Until recently, we lacked any scores that were derived 
specifically from patients being treated with anticoagulants for VTE.  Thus, we cannot 
recommend a specific risk score in patients with COVID-19.  Several risk scores have been 
suggested, and many of the variables overlap between scores.  We suggest that providers rely 
on institutional methods for assessing bleeding risk and would refer the reader to items noted 
to be associated with increased risk of bleeding as outlined in the most recent CHEST 
Guidelines
20
 (age, previous bleeding, cancer, renal failure, liver failure, thrombocytopenia, 
previous stroke, diabetes, anemia, antiplatelet therapy. Poor anticoagulant control, 
comorbidities, recent surgery, frequent falls, alcohol abuse, non-steroidal anti-inflammatory 
use). 
 
16. In most patients with COVID-19 and acute, objectively confirmed PE not associated 
with hypotension (systolic blood pressure < 90 mm Hg or blood pressure drop of >= 
40 mm Hg lasting longer than 15 minutes), we recommend against systemic 
thrombolytic therapy. 
 
Remarks:  Please see statement 18 for the select patients that may require systemic 
thrombolysis. 
 
17. In patients with COVID-19 and both acute, objectively confirmed PE and hypotension 
(systolic BP < 90 mm Hg) or signs of obstructive shock due to PE, and who are not at 
high risk of bleeding, we suggest systemically administered thrombolytics over no 
such therapy. 
 
18. In patients with COVID-19 and acute PE with cardiopulmonary deterioration due to 
PE (progressive increase in heart rate, a decrease in systolic BP which remains >90 
mm Hg, an increase in jugular venous pressure, worsening gas exchange, signs of 
shock (eg, cold sweaty skin, reduced urine output, confusion), progressive right heart 
dysfunction on echocardiography, or an increase in cardiac biomarkers) after 
initiation of anticoagulant therapy who have not yet developed hypotension and who 
have a low risk of bleeding, we suggest systemic thrombolytic therapy over no such 
therapy. 
 
19. We recommend against the use of any advanced therapies (systemic thrombolysis, 
catheter-directed thrombolysis or thrombectomy) for most patients without 
objectively confirmed VTE. 
Remarks:  Thrombolysis may be considered in select patients when cardiac arrest is 
suspected to be caused by PE and imaging is not obtainable.  We would suggest that 
 
providers consider the differential of right ventricular strain (preexisting pulmonary 
hypertension, high PEEP, severe ARDS) before entertaining the use of empiric 
thrombolysis. 
 
20. In those patients with COVID-19 receiving thrombolytic therapy, we suggest systemic 




Recurrent Venous Thromboembolism 
 
Our literature search did not identify any randomized trials assessing the efficacy and safety of 
different anticoagulation regimens for the management of recurrent VTE despite 
anticoagulation in patients with COVID-19.  There are no randomized trials or prospective 
cohort studies that have evaluated management of patients with recurrent VTE despite 
anticoagulation. Important factors to consider include compliance, adequate absorption of 
DOACs and absence of potential drug-to-drug interactions. 
 
Due to the absence of direct evidence, the guideline panel decided to consider indirect 
evidence (low-quality) available from other another population at high risk of recurrent VTE, 
patients with cancer-associated thrombosis. There are no studies assessing the treatment of 
recurrent VTE despite anticoagulation with DOACs. One retrospective study reported 
 
reasonable outcomes (recurrent VTE of 9% [95% CI: 2 to 25%]) when using therapeutic weight-
adjusted LMWH in patients with recurrent VTE despite oral anticoagulation with vitamin K 
antagonists.
66
  Two small retrospective cohort studies have also reported reasonable outcome 
by increasing the dose of LMWH to 125% and 130% in patients with recurrent events despite 
therapeutic weight-adjusted LMWH.
67,68
  The rate of recurrent VTE and major bleeding was 
8.6% (6/70, 95% CI 4.0-17.5%) and 4.3% (3/70; 95% CI 1.5-11.9%), respectively, among patients 
receiving increased dose (125 to 130%) of LMWH.
67
 Finally, an International Society of 
Thrombosis and Haemostasis registry showed comparable findings to the aforementioned 
studies.
69
  Based on indirect comparisons, we expect the net benefit of increasing the dose of 
LMWH by 25 to 30% in patients with COVID-19 and recurrent VTE despite therapeutic 
anticoagulation with LMWH and switching to LMWH in patients failing oral anticoagulation with 
a DOAC or vitamin K antagonist. 
 
21. In patients with COVID-19 and recurrent VTE despite anticoagulation with 
therapeutic weight adjusted LMWH (and documented compliance), we suggest 
increasing the dose of LMWH by 25 to 30%. 
 
 
22. In patients with COVID-19 and VTE despite anticoagulation with apixaban, 
dabigatran, rivaroxaban or edoxaban (and documented compliance), or vitamin K 
antagonist therapy (in the therapeutic range) we suggest switching treatment to 






The guidance statements in this document were specifically created to address what were felt 
to be common, urgent clinical questions that frontline providers are likely to face regarding 
venous thromboembolism and hypercoagulability in patients with COVID-19.  
  
There are important limitations with this guidance. First is the lack of direct evidence to inform 
the guidance. Clearly more is being shared on a daily basis, but this emphasizes the importance 
of enrolling patients in clinical trials wherever possible and the need for international 
collaboration in collecting and rapidly disseminating relevant clinical experience, gaps in 
knowledge, and the research agenda.  Second, due to the urgency of the situation, the panel 
was unable to address all of the likely questions that have arisen.  As we consider this a living 
document that will be updated, we will incorporate additional questions to these updates as 
needed. Finally, and perhaps most importantly, the current body of evidence does not allow us 
to delineate between macro (DVT/PE) and microthrombosis, and the approach to these may 
differ.  It is possible that studies looking for the prevalence of DVT and PE fail to represent the 
microthrombosis which could drive at least a portion of mortality in these patients. 
 
The strengths of this document are the multidisciplinary panel that was composed of 
experienced clinicians and researchers in the field, many with extensive experience in the 
development of evidence-based guidelines.  In addition, despite the lack of a robust evidence 
 
base, the panel followed a robust methodologic approach to formulate specific questions, 
evaluate the literature, and seek consensus. 
 
We must acknowledge that there are over 10 other international guidelines, guidance 
statements, or online references that address this topic (although most focus on prevention, 
not diagnosis or treatment).
70-80
  While this can seem overwhelming, the authors would like to 
emphasize the relative consistency in these statements.  Most of these guidelines recommend 
VTE prevention in all hospitalized patients with COVID-19,
70,71,73,75-77
  while some do 
recommend risk assessment to guide the decision.
72,74,79
  As we discussed earlier, given the 
underlying risk factors present in these patients and that the current estimates of the incidence 
of VTE in non-critically ill patients with COVID-19 is well above 1% even on anticoagulant 
thromboprophylaxis, the panel considers all hospitalized patients with COVID-19 at increased 
risk of VTE. We therefore suggest against individualized VTE risk assessment and suggest 
anticoagulant thromboprophylaxis in all hospitalized patient with COVID-19 in the absence of 
contraindications.  Almost all of these documents recommend standard dosing for 
anticoagulant thromboprophylaxis.  One mentions escalating the dose, stating that it can be 
considered in patients with a large increase in the D-dimer level or severe respiratory failure.
73
  
Another suggests increased dosing in the critically ill patient with COVID-19, but recognizes that 
this was based largely on expert opinion.
80
  The statements are consistent in the 
recommendation for the use of LMWH or UFH in COVID-19 patients.  Those that address the 
use of mechanical prophylaxis note that it should be used in patients with a 
contraindication,
70,71,75,79,80
 or can be added to anticoagulant thromboprophylaxis in patients 
 
who are completely immobilized.
74,80
  Finally, only a few of these statement address the issue of 
extended duration prophylaxis.  Bikdeli and colleagues note that there is no data in this 
population, although they state that it would be reasonable to take an individualized approach 
in each patient after risk stratifying for both thrombosis and bleeding risk.
72
  The Italian Society 
on Thrombosis and Haemostasis recommends prophylaxis throughout the hospitalization and 
for an addition 7-10 days post discharge.
75
  The American Society of Hematology recommends 
following current guidelines, which recommend against extended duration prophylaxis in 
hospitalized medical patients.
22,71
  As we noted earlier, we endorse this approach because the 
post-discharge VTE and major bleeding rates in COVID-19 patients are currently unknown. 
 
It is our hope that clinicians caring for patients with COVID-19 will find this document helpful.  
Clearly, we still need well designed randomized trials to answer many of our pressing questions. 
These include optimal dosing of prophylactic anticoagulant therapy, patients who might benefit 
from full dose anticoagulant treatment, and the unique role of macro and microthombosis in 
COVID-19.  We hope that this version of guidance will serve as a call to enroll patients in clinical 
trials wherever possible.  We would also like to use this document as a call to reason.  We are in 
a time of unprecedented economic, social, and medical uncertainty.  We have been trained to 
accept uncertainty, and to be wary of undesirable consequences of acting too quickly on new 
observations that may not affect our usual care.  As physicians, we are trained to practice 
evidence-based medicine.  We need to always remember that any intervention can cause harm.  
In a time when our decisions may be driven by emotion, we risk the tendency to rely on 
anecdotes and early, small case series or cohorts.  As recently stated by Zagurly-Orly and 
 
Schwartzstein, “We must reason critically and reflect on the biases that may influence our 
thinking processes, critically appraise evidence in deciding how to treat patients, and use 
anecdotal observations only to generate hypotheses for trials that can be conducted with 
clinical equipoise. We must act swiftly but carefully, with caution and reason”.
81
  We look 
forward to updating this guidance when well-designed trials have been completed. 
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Table 1.  PICO Questions  
 
 
 Population Intervention Comparator Outcomes 
Question 1 Patients with COVID-19 Standard dose UFH, 
LMWH, Fondaparinux 
Placebo VTE, bleeding, 
mortality 
Question 2 Patients with COVID-19 Intermediate dose 
anticoagulant 
thromboprophylaxis 
Standard dose VTE, bleeding, 
mortality 




intermediate dose  
VTE, bleeding, 
mortality 
Question 4 Patients with COVID-19 Extended duration 
prophylaxis (45 days) 




Question 5 Patients with COVID-19 Antiplatelet agent 
prophylaxis 




Question 6 Patients with COVID-19 Combined 
mechanical and 
chemical prophylaxis 
Chemical prophylaxis VTE, bleeding, 
mortality 





UFH Recurrent VTE, 
bleeding, mortality 
Question 8 Patients with COVID-19 
and objectively 
confirmed VTE  




Question 9 Patients with COVID-19 
and objectively 
confirmed VTE while 




LMWH or UFH 





Question 10 Patients with COVID-19 
and objectively 
confirmed VTE while 
on treatment dose 
anticoagulant 
125-130% dose 
LMWH or UFH 





Question 11 Patients with COVID-19 Routine screening US No screening US Symptomatic VTE 








Question 13 Patients with COVID-19 Fibrinogen, PTT, PT, 




TEG, DIC score negative, false 
positive, efficiency 
 
Table 2. Characteristics of studies reporting on pr evalence or incidence of VTE in patients with COVID -19. 














Cui et al.4 Retrospective cohort China 1 Yes Unclear No 81 / NA Mean 
60 
Yes NR 
Klok et al.6,7 Retrospective cohort The 
Netherlands 





184 / NA Mean 
64 
No NR 




45/150 (30%) therapeutic 
heparin 





Prospective cohort Italy 1 Yes Unclear Intermediate-dose 
nadroparinb 





Prospective cohort Italy 1 Yes Consecutive ICU 
admissions 
Anticoagulant prophylaxis 22 / NA Mean 
67 
NR NR 
Llitjos et al.8 Retrospective cohort France 2 Yes Consecutive ICU 
admissions 
8/26 (31%) prophylactic 
heparin; 18/26 (69%) 
therapeutic heparin 









heparin; 17/61 (28%) 
weight-adjusted 
prophylactic heparin; 2/61 
(3%) therapeutic heparin 





Retrospective cohort France 1 Yes Consecutive ICU 
admissions 





Retrospective cohort United 
Kingdom 
1 Yes Consecutive ICU 
admissions 
Weight-adjusted heparin 
at prophylactic dose 





Retrospective cohort The 
Netherlands 






75 / 123 Mean 
61 
Partlyf Yes 
Xu et al.14 Retrospective cohort China 1 No Unclear Anticoagulant prophylaxis 
in at risk populationg 
15 / 123 Mean 
52 
Partlyh NR 
Abbreviations: DVT, deep vein thrombosis; ICU, intensive care unit; NA, not applicable; NR, not reported; PE, pulmonary embolism; VTE, venous thromboembolism. 
 
a During the study period, the dose of thromboprophylaxis with nadroparin was doubled in 2 of 3 participating centers; 17/184 (7.2%) patients were on therapeutic anticoagulation at 
admission. 
b Nadroparin 4000 units twice daily which was increased to nadroparin 6000 units twice daily (or 8000 units twice daily if BMI >35 kg/m2) in all patients after performance of coagulation 
and viscoelastic tests. 
c Of the patients with PE, 20 received prophylactic heparin, 1 therapeutic heparin, and 1 vitamin K antagonist with therapeutic INR at time of diagnosis. 
d 7/75 (9.3%) patients in the ICU and 12/123 (10%) patients on the ward continued therapeutic anticoagulation for an indication that was present at time of admission; none of those 
patients developed a VTE. 
e During the study period, the dose of thromboprophylaxis with nadroparin was doubled for patients admitted to the ICU. 
f Screening ultrasound for lower extremity DVT was performed in 38/75 (51%) critically ill patients and 17/123 (14%) patients on the ward. 
g Patients with a Padua score ≥4 points were considered at risk for VTE; “routine thromboprophylaxis” was given to 15/15 (100%) ICU patients and 26/123 (21%) ward patients. 
h Screening ultrasound for lower extremity DVT was performed in all critically ill patients; no screening was performed in patients on the ward. 
  
 















Cui et al.4 NR NR 20/81 (25%) NR NR NR NR 8/81 (10%) 
Klok et al.6,7 Median 14 days 65/184 (35%) 1/184 (0.5%) 1/184 (0.5%) 65/184 (35%) 46/184 (25%) NR 41/184 (22%) 
Helms et al.5 Mean 9.6 days 100/150 (67%) 3/150 (2.0%) NR 25/150 (17%) 22/150 (15%) 4/150 (2.7%) 13/150 (8.7%) 
Ranucci et al.25 NR 3/16 (19%) 0 0 0 0 NR 7/16 (44%) 
Spiezia et al.12 NR NR 5/22 (23%) NR NR NR NR NR 
Llitjos et al.8 NR 7/26 (27%) 14/26 (54%)a NR 6/26 (23%)b NR NR 3/26 (12%) 
Lodgiani et al.9 Median 18 days 13/61 (21%) 1/61 (1.6%) Unclearc 2/61 (3.3%) NR NR NRd 
Poissy et al.11 NR 22/107 (21%) 2/107 (1.9%) NR 22/107 (21%) Unclear NR 15/107 (14%) 
Thomas et al.13  Median 8 days 28/62 (45%) 0 0 5/62 (8.1%) 4/62 (6.5%) NR 10/62 (16%) 
Middeldorp et al.10 Median 15 days NRe 23/75 (31%) 14/75 (19%) 11/75 (15%) 10/75 (13%) NR NRf 
Xu et al.14 NR NR 3/15 (20%) NR NR NR NR NR 
Abbreviations: DVT, deep vein thrombosis; NR, not reported; PE, pulmonary embolism; VTE, venous thromboembolism. 
a 6  patients on thromboprophylaxis at prophylactic doses; 7  on thromboprophylaxis at therapeutic doses, thromboprophylaxis dose for 1 patient not reported. 
b 6/14 patients on thromboprophylaxis at therapeutic doses. 
c Inconsistent reporting of distal versus proximal DVT in published article. 
d In the entire study population, 92/388 (24%) patients died. 
e In the entire study population, 16/198 (8%) patients were still admitted at time of data analysis. 
f In the entire study population, 38/198 (19%) patients died. 
  
 















Lodgiani et al.9 Median 9 days 13/327 (4%) 4/327 (1.2%) 3/327 (0.9%) 8/327 (2.4%) NR NR NRa 
Middeldorp et al.10 Median 4 days NRb 2/123 (1.6%) 0/124 2/123 (1.6%) 1/123 (0.8%) NR NRc 
Xu et al.14 NR NR 1/123 (0.8%) NR NR NR NR NR 
Abbreviations: DVT, deep vein thrombosis; NR, not reported; PE, pulmonary embolism; VTE, venous thromboembolism. 
a In the entire study population, 92/388 (24%) patients died. 
b In the entire study population, 16/198 (8%) patients were still admitted at time of data analysis. 
c In the entire study population, 38/198 (19%) patients died. 
 
 
 
 
 
 
 
 
